logo-loader

VentriPoint Diagnostics' VMS+ system to be used in clinical trials at Mazankowski heart institute

Last updated: 05:54 22 Feb 2018 AEDT, First published: 22:54 21 Feb 2018 AEDT

price screen
The centre has world class technology, said Ventripoint

VentriPoint Diagnostics Ltd (CVE:VPT) is set for results from two clinical studies which will use the VMS+ whole heart analysis system after the device was installed at the University of Alberta.

To be more specific, at the Mazankowski Alberta Heart Institute in Edmonton.

Desmond Hirson, the president of Ventripoint, added: "We are pleased that the VMS+ is operational at Mazankowski and look forward to the results from two innovative clinical studies that will highlight the increased abilities of the VMS+ to analyze the heart and improve patient care."

Mazankowski is integrated with the University of Alberta and Stollery Children's Hospitals, making it one of the very few heart institutes to accommodate both adult and pediatric patients.

The Mazankowski, said Ventripoint, has one of the most  advanced Echo Labs in the world providing leading-edge imaging techniques such as 3D, contrast, myocardial perfusion, speckle tracking and interventional echo.

Earlier this month, the group revealed it had hired Dr Andriy Shmatukha as software developer to advance the group's products.

The firm has developed applications to monitor heart disease, a leading cause of death worldwide.

Shmatukha is a qualified network administrator with over 18 years of medical device R&D (research and development) experience with emphasis on diagnostics cardiac imaging, including the development of image analysis algorithms and associated software.

In a note to stakeholders, Ventripoint chief executive George Adams said the centre had previously just a VMS for right ventricle only but had now upgraded to the version for all four chambers of the heart.

He said they will try it out on a select group of patients until they adopt it for everyone.  

Accordingly, they are going to study “technically-difficult” (who give poor images) patients first and then cancer patients.

Shares in Toronto eased 1.56% to C$0.32.

VentriPoint Diagnostics gets gateway CE mark

Toronto-listed medtech firm VentriPoint Diagnostics Ltd (CVE:VPT) has announced a major step forward for its breakthrough whole heart analysis system - a European CE mark. Dr.George Adams, CEO, tells Proactive how this is a 'gateway' moment to other markets worldwide with hypertension...

on 11/1/18